BrainsWay (TASE:BWAY) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

BWAY Overzicht aandelen

BrainsWay Ltd. ontwikkelt en verkoopt niet-invasieve neurostimulatiebehandelingen voor psychische stoornissen in de Verenigde Staten en internationaal.

Over het bedrijf

BWAY fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	4/6
Prestaties in het verleden	3/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 73.7% onder onze schatting van de reële waarde

De winst zal naar verwachting met 70.75% per jaar groeien

Dit jaar winstgevend geworden

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

BrainsWay Ltd. Concurrenten

Epitomee Medical

TASE:EPIT

₪249.3m

SofWave Medical

TASE:SOFW

₪615.1m

Pulsenmore

TASE:PULS

₪198.2m

Bio-View

TASE:BIOV

₪35.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor BrainsWay
Historische aandelenkoersen
Huidige aandelenkoers	₪17.11
52 Week Hoogtepunt	₪17.84
52 Week Laag	₪6.52
Bèta	0.32
11 maand verandering	21.35%
3 maanden verandering	54.28%
1 Jaar Verandering	116.86%
33 jaar verandering	33.78%
5 jaar verandering	10.74%
Verandering sinds IPO	10.93%

Recent nieuws en updates

After Leaping 27% BrainsWay Ltd. (TLV:BWAY) Shares Are Not Flying Under The Radar

Aug 23

Recent updates

After Leaping 27% BrainsWay Ltd. (TLV:BWAY) Shares Are Not Flying Under The Radar

Aug 23

We Think BrainsWay (TLV:BWAY) Can Easily Afford To Drive Business Growth

May 03

BrainsWay Ltd.'s (TLV:BWAY) P/S Is Still On The Mark Following 26% Share Price Bounce

Dec 25

What Type Of Returns Would Brainsway's(TLV:BWAY) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 25

Brainsway Ltd. (TLV:BWAY): Is Breakeven Near?

Dec 26

Rendement voor aandeelhouders

	BWAY	IL Medical Equipment	IL Markt
7D	10.7%	3.5%	2.8%
1Y	116.9%	4.8%	3.2%

Rendement versus industrie: BWAY overtrof de IL Medical Equipment industrie, die het afgelopen jaar een rendement 6.1 % opleverde.

Rendement versus markt: BWAY overtrof de IL markt, die het afgelopen jaar een rendement opleverde van 3.9 %.

Prijsvolatiliteit

Is BWAY's price volatile compared to industry and market?
BWAY volatility
BWAY Average Weekly Movement	7.3%
Medical Equipment Industry Average Movement	6.9%
Market Average Movement	4.3%
10% most volatile stocks in IL Market	7.1%
10% least volatile stocks in IL Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van BWAY is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van BWAY is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen IL.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2003	134	Hadar Levy	www.brainsway.com

BrainsWay Ltd. ontwikkelt en verkoopt niet-invasieve neurostimulatiebehandelingen voor psychische aandoeningen in de Verenigde Staten en internationaal. Het biedt Deep Transcranial Magnetic Stimulation-platformtechnologie voor de behandeling van depressieve stoornissen, angststoornissen, obsessieve-compulsieve stoornissen, rookverslaving, bipolaire stoornissen, posttraumatische stressstoornissen, schizofrenie, de ziekte van Alzheimer, autisme, chronische pijn, multiple sclerose, revalidatie na een beroerte en de ziekte van Parkinson. Het bedrijf bedient artsen, ziekenhuizen en medische centra op het gebied van psychiatrie.

BrainsWay Ltd. Samenvatting

Hoe verhouden de winst en inkomsten van BrainsWay zich tot de beurswaarde?
BWAY fundamentele statistieken
Marktkapitalisatie	₪570.72m
Inkomsten(TTM)	₪2.29m
Inkomsten(TTM)	₪137.33m

249.0x

Koers/Winstverhouding

4.2x

P/S-verhouding

Is BWAY overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BWAY resultatenrekening (TTM)
Inkomsten	US$36.43m
Kosten van inkomsten	US$9.17m
Brutowinst	US$27.26m
Overige uitgaven	US$26.65m
Inkomsten	US$608.00k

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.018
Brutomarge	74.82%
Nettowinstmarge	1.67%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde BWAY op de lange termijn?

Bekijk historische prestaties en vergelijking

BWAY Overzicht aandelen

Beloningen

Risicoanalyse

BrainsWay Ltd. Concurrenten

TASE:EPIT

₪249.3m

TASE:SOFW

₪615.1m

TASE:PULS

₪198.2m

TASE:BIOV

₪35.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli

BrainsWay Ltd. Appoints Richard A. Bermudes, M.D. as Chief Medical Officer, Effective September 1, 2024

After Leaping 27% BrainsWay Ltd. (TLV:BWAY) Shares Are Not Flying Under The Radar

New major risk - Share price stability

Second quarter 2024 earnings released: EPS: US$0.02 (vs US$0.05 loss in 2Q 2023)

BrainsWay Ltd. Updates Revenue Guidance for the Full Year of 2024

Recent updates

Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli

BrainsWay Ltd. Appoints Richard A. Bermudes, M.D. as Chief Medical Officer, Effective September 1, 2024

After Leaping 27% BrainsWay Ltd. (TLV:BWAY) Shares Are Not Flying Under The Radar

New major risk - Share price stability

Second quarter 2024 earnings released: EPS: US$0.02 (vs US$0.05 loss in 2Q 2023)

BrainsWay Ltd. Updates Revenue Guidance for the Full Year of 2024

BrainsWay Ltd. to Report Q2, 2024 Results on Aug 06, 2024

BrainsWay Ltd. Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS for Depression for the Month of June 2024

BrainsWay Ltd. Receives Expanded FDA Labeling to Treat Late Life Depression

BrainsWay Ltd., Annual General Meeting, Jun 17, 2024

First quarter 2024 earnings released: EPS: US$0.003 (vs US$0.07 loss in 1Q 2023)

BrainsWay Ltd. Reiterates Revenue Guidance for the Year 2024

We Think BrainsWay (TLV:BWAY) Can Easily Afford To Drive Business Growth

BrainsWay Ltd. to Report Q1, 2024 Results on May 08, 2024

BrainsWay Ltd. Announces Publish Review Results Highlighting Potential of Deep Transcranial Magnetic Stimulation (Deep TMS™) as a Novel Therapeutic Approach for Parkinson's Disease

Brainsway Announces Positive Results in Late-Life Depression Post-Marketing Analysis

Full year 2023 earnings released: US$0.13 loss per share (vs US$0.41 loss in FY 2022)

New major risk - Revenue and earnings growth

Brainsway Ltd. Provides Earnings Guidance for Full Year 2024

BrainsWay Ltd. to Report Q4, 2023 Results on Mar 06, 2024

New minor risk - Market cap size

BrainsWay Ltd. Announces New Rotational Field Technology in Two New Feasibility Studies

BrainsWay Ltd.'s (TLV:BWAY) P/S Is Still On The Mark Following 26% Share Price Bounce

We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.15 loss in 3Q 2022)

BrainsWay Ltd. Announces Publishes the First Coverage Recommendations for Smoking Addiction Treatment Using TMS

BrainsWay Ltd. to Report Q3, 2023 Results on Nov 15, 2023

BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) for Depression

We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely

Forecast to breakeven in 2025

BrainsWay Ltd. to Report Q2, 2023 Results on Aug 09, 2023

We're Keeping An Eye On BrainsWay's (TLV:BWAY) Cash Burn Rate

Brainsway Ltd. Announces CFO Changes

No longer forecast to breakeven

BrainsWay Ltd. to Report Q1, 2023 Results on May 17, 2023

Full year 2022 earnings released: US$0.40 loss per share (vs US$0.21 loss in FY 2021)

BrainsWay Ltd., Annual General Meeting, Mar 20, 2023

BrainsWay Ltd. Appoints Ami Boehm as an Independent Director

BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™

Neuronetics Settles Litigation Against BrainsWay Ltd. and BrainsWay USA Inc

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.05 loss in 3Q 2021)

No longer forecast to breakeven

BrainsWay Ltd. to Report Q3, 2022 Results on Nov 16, 2022

BrainsWay Ltd Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS

BrainsWay Ltd. Receives New FDA Clearance for Treating Depression and Anxious Depression

We Think BrainsWay (TLV:BWAY) Can Afford To Drive Business Growth

Second quarter 2022 earnings released: US$0.07 loss per share (vs US$0.06 loss in 2Q 2021)

No longer forecast to breakeven

BrainsWay Ltd. to Report Q2, 2022 Results on Aug 10, 2022

BrainsWay Ltd. Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression

Brainsway Announces Positive OCD Coverage Policy from Blue Cross Blue Shield® (BCBS) Licensee Highmark BCBS for Deep TMS™

BrainsWay Ltd. Promotes Hadar Levy to Senior Vice President and Chief Operating Officer

BrainsWay (TLV:BWAY) Is In A Good Position To Deliver On Growth Plans

First quarter 2022 earnings released: US$0.06 loss per share (vs US$0.11 loss in 1Q 2021)

Neuronetics, Inc. Files Federal Lawsuit Against BrainsWay Ltd. for Misleading Psychiatrists and Patients

BrainsWay Ltd. to Present Expanded Post-Marketing Clinical Research for Major Depressive Disorder at Clinical TMS Society

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

BrainsWay Ltd. to Report Q4, 2021 Results on Mar 09, 2022

BrainsWay (TLV:BWAY) Is In A Strong Position To Grow Its Business